Healthcare / Pharmaceutical RetailersShenzhen
$10.19
-0.41 (-3.87%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 35% · confianza 12%
FCF escenarios
weak_data · normalized FCF $-199.6M · quality 27.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.1B
P/E
N/A
•EV/EBITDA
120.9x
↑ROE
-16.3%
↓Gross Margin
18.2%
↓Debt/Equity
2.47
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+16.0%
FCF CAGR
—
FCF margin
-4.9%
FCF / Net income
1.05x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $5.14B · net income $-242.5M · FCF $-253.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $5.14B | $5.14B | $5.23B | $3.90B | $3.29B |
| Net Income | $-242.5M | $-242.5M | $26.6M | $34.3M | $51.1M |
| EBITDA | $42.8M | $42.8M | $321.4M | $195.1M | $155.9M |
| EPS | -1.18 | -1.18 | 0.13 | 0.17 | 0.25 |
| Gross Margin | 18.2% | 18.2% | 19.9% | 14.8% | 12.0% |
| Operating Margin | 2.1% | 2.1% | 4.0% | 3.7% | 4.1% |
| Net Margin | -4.7% | -4.7% | 0.5% | 0.9% | 1.6% |
| Balance Sheet | |||||
| Debt/Equity | 2.47 | 2.47 | 1.87 | 1.47 | 0.94 |
| Current Ratio | 1.01 | 1.01 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-253.8M | $-253.8M | $-163.1M | $-199.6M | $-702.7M |
| Returns | |||||
| ROE | -16.3% | -16.3% | 1.5% | 2.0% | 3.0% |
| Valuation | |||||
| P/E | — | — | 76.15 | 78.12 | 61.28 |
| EV/EBITDA | 120.93 | 120.93 | 14.59 | 23.60 | 26.92 |
| P/B | 1.41 | 1.41 | 1.15 | 1.53 | 1.82 |
| Growth & Yield | |||||
| Revenue Growth | -1.7% | -1.7% | 34.1% | 18.6% | — |
| EPS Growth | -1007.7% | -1007.7% | -23.5% | -32.0% | — |
| Dividend Yield | 1.0% | 1.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-6.6%
Start / end P/E
n/dx → n/dx
EPS bridge
0.13 → -1.18
Residual
-7.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.